EJMA

DOI: 10.14744/ejma.2024.18199
EJMA 2024;4(2):110–111

Letter to the Editor

Emerging Frontiers in Cancer Diagnosis: The Marvel of Protein Detection Technologies

Sawera Haider

Department of Surgery, Dr. Ruth K. M. Pfau Civil Hospital, Karachi, Pakistan

Cite This Article: *Haider S. Emerging Frontiers in Cancer Diagnosis: The Marvel of Protein Detection Technologies. EJMA 2024;4(2):110–111.*

In recent years, significant advancements have been made in the field of cancer diagnosis, leading to improved outcomes for patients. One such breakthrough is the development of novel protein detection methods. Protein detection techniques are used to identify cancer by analysing the presence, activity, and levels of specific proteins in cancer cells or tissues. These techniques provide valuable information about the molecular changes that occur in cancer and can be used for diagnosis, prognosis, and therapy monitoring.

Ground-breaking protein detection techniques can now offer new insight into the study of malignant tumours by identifying protein biomarkers for early detection, stratification, prediction, and monitoring of treatment.[1] These biomarkers are responsible for regulating the cell cycle, promoting cell proliferation, and resistance to cell mortality in cancer cells.[2]

The bellwether technologies used in protein detection include enzyme-linked immunosorbent assay (ELISA), Immunohistochemistry (IHC), flow cytometry, western blot, mass spectrometry, protein microarray, and microfluidics.[3] These techniques allow for screening, protein profiling, identification, qualitative and quantitative analysis of differentially expressed oncoproteins in cancer tissues. They also enable the identification of tissue-specific proteins and the analysis of protein activity modifications in cancer conditions.

Compared to traditional diagnostic methods, protein detection is leaps and bounds ahead. It provides improved sensitivity and specificity in cancer diagnosis, allowing for more accurate detection and measurement of protein activity. It is also more efficient and cost-effective, as it can be performed using smaller sample sizes and requires less manual intervention.[4]

Furthermore, protein detection techniques can be used for non-invasive procedures, such as blood; urine; stool; or saliva tests, which are preferred by patients due to their lower pain and higher compliance rates.[5] These non-invasive assays can also be used for frequent monitoring of treatment response.

Nevertheless, while these methods have greatly advanced our understanding of the disease and improved diagnostic accuracy, they are not without challenges.

One limitation is the lack of integration and standardisation of information obtained from different protein diagnostic technologies. To obtain optimal information for the clinical management of patients, it is crucial to integrate data from these techniques effectively. Data integration, however, requires the development of intricate standardised protocols and data analysis methodologies - which would be complex and time-consuming.[6]

Another latent pitfall is the potential for false positives or negatives in protein diagnostic tests, which can lead to misdiagnosis or undetected cancer cases. Diagnostic imaging technologies, in particular, may cause unnecessary stress and worry, and can overlook minor lesions, leading to late-stage detection.

Address for correspondence: Sawera Haider, MD. Department of Surgery, Dr. Ruth K. M. Pfau Civil Hospital, Karachi, Pakistan
Phone: +92-336-3438378 **E-mail:** swerahaider99@gmail.com

Submitted Date: December 07, 2023 **Revision Date:** December 07, 2023 **Accepted Date:** June 25, 2024 **Available Online Date:** September 10, 2024

Despite these limitations, protein detection undoubtedly remains invaluable in cancer diagnosis. It has proven revolutionary, providing valuable insights into the disease and improving patient outcomes. While there are legitimate limitations to be addressed, ongoing advancements in proteomic technologies undeniably hold the potential for further improving the accuracy, sensitivity, and efficiency of protein detection in the realm of cancer diagnosis.

Disclosures

Peer-review: Externally peer-reviewed.

Conflict of Interest: None declared.

References

1. Misek DE, Kim EH. Protein biomarkers for the early detection of breast cancer. Int J Proteomics 2011;2011:343582.
2. Li K, Wu D, Chen X, Zhang T, Zhang L, Yi Y, et al. Current and emerging biomarkers of cell death in human disease. BioMed Res Int 2014;2014:690103.
3. Fredolini C, Byström S, Pin E, Edfors F, Tamburro D, Iglesias MJ, et al. Immunocapture strategies in translational proteomics. Expert Rev Proteomics 2016;13(1):83–98.
4. Powers AD, Palecek SP. Protein analytical assays for diagnosing, monitoring, and choosing treatment for cancer patients. J Healthc Eng 2012;3(4):503–534.
5. Loktionov A. Biomarkers for detecting colorectal cancer non-invasively: DNA, RNA or proteins? World J Gastrointest Oncol 2020;12(2):124–148.
6. Huang CH, Peng HS, Ng KL. Prediction of cancer proteins by integrating protein interaction, domain frequency, and domain interaction data using machine learning algorithms. BioMed Res Int 2015;2015:312047.